Skip to main content
Publications
Petri M, Landy H, Clowse MEB, Gemzoe K, Khamashta M, Kurtinecz M, Levy RA, Liu A, Marino R, Meizlik P, Pimenta JM, Sumner K, Tilson H, Connolly MB, Wurst K, Harris J, Quasny H, Juliao P, Roth DA. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis. 2023 Feb;82(2):217-25. doi: 10.1136/ard-2022-222505
Ogdie A, Mansfield C, Myers K, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh JA. Real-world patient experience and treatment preferences in patients with psoriatic arthritis. Poster presented at the Virtual EULAR 2021 Congress; June 2, 2021. [abstract] Ann Rheum Dis. 2021 Jun; 80(Suppl 1):237. doi: 10.1136/annrheumdis-2021-eular.852
Husni ME, Bozyczko M, Wolin D, Sweeney C, Davenport E, Hass S, Yi E, Hur P, Grinnell-Merrick L. A prospective, longitudinal study to evaluate real-world patient experiences and treatment satisfaction with secukinumab for psoriatic arthritis. Poster presented at the Virtual EULAR 2021 Congress; June 2, 2021. [abstract] Ann Rheum Dis. 2021 Jun; 80(Suppl 1):808-9.
Zeng X, Leng X, Wei K, Tang WM, Tang CH, Tunceli K, Aggarwal J, Ramey D, Lozano F, Doshi I, Macahilig C, Odak S, Johnson K. Results from a cross-sectional, observational study to assess inadequate pain relief in patients with knee and/or hip osteoarthritis in China. Poster presented at the 2020 Virtual Annual European Congress of Rheumatology (EULAR); June 5, 2020. [abstract] Ann Rheum Dis. 2020 Jun; 79(Suppl 1):812-3. doi: 10.1136/annrheumdis-2020-eular.5813
Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomised, controlled study in biologic-naÏve subjects with active psoriatic arthritis. Poster presented at the EULAR 2018 Annual European Congress of Rheumatology; June 13, 2018. Amsterdam, The Netherlands. [abstract] Ann Rheum Dis. 2018 Jun 12; 77(Suppl 2):A1598. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.1136/annrheumdis-2018-eular.3139
Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens JL, Fautrel B, Uhlig T, van Vollenhoven R, Jacques P, Detert J, Canas da Silva J, Scire CA, Berghea F, Carmona L, Pentek M, Keat A, Boonen A. Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Ann Rheum Dis. 2017 Jan;76(1):126-32. doi: 10.1136/annrheumdis-2016-209202
White MV, Hogue SL, Bennett ME, Goss D, Millar K, Hollis K, Siegel PH, Wolf RA, Wooddell M, Silvia S. EpiPen4Schools pilot survey: occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting. Allergy Asthma Proc. 2015 Jul;36(4):306-12. doi: 10.2500/aap.2015.36.3859
Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, Kaiser HB, Vandewalker ML, Bernstein J, Toler WT, Prillaman BA, Dalal AA, Lee LA, Philpot EE. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009 Mar;30(2):128-38. doi: 10.2500/aap.2009.30.3204